Date: 19 Oct 2012
Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Dopamine agonists have a well established role in the treatment of Parkinson’s disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.
Objective: The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (bromocriptine, cabergoline, pramipexole, rotigotine, pergolide) and placebo in monotherapy and adjuvant therapy with levodopa in the treatment of Parkinson’s disease, as reported in the peer reviewed medical literature.
Methods: A systematic review of the medical literature was carried out for relevant English language articles in the MEDLINE database and Cochrane Library from January 1975 to November 2008. The searches were limited to either double-blind clinical trials or randomized clinical trials that included both patients with early Parkinson’s disease receiving dopamine agonist monotherapy, and patients at a later stage on combined treatment with levodopa. The Cochrane Collaboration guidelines were followed and the following data were extracted from each study: identifier (title and bibliographical reference), classification of the quality of the evidence (Jadad criteria), type and design of the study, number of patients, patient demographics (average age, sex), Parkinson’s disease stage (Hoehn and Yahr Scale), treatment (monotherapy or adjuvant to levodopa), drugs used (including dosage and duration), study objective (safety or tolerability), method of evaluation of results, randomization and blinding, and description of all the adverse events in all treatment groups. A meta-analysis was performed, calculating relative risks (RRs) and confidence intervals for the 12 most relevant adverse events. On the basis of incidence and clinical importance criteria, the final selection of 12 adverse events was made by consensus between the investigators.
Results: Forty randomized clinical trials were included. Direct comparison of ropinirole with bromocriptine showed a lower RR of constipation for ropinirole (0.55 [95% CI 0.35, 0.89]), while the direct comparison with levodopa showed a lower RR of dyskinesia for ropinirole (0.25 [95% CI 0.09, 0.71]); no significant differences for either dyskinesia or constipation were found when a direct comparison of ropinirole and rotigotine was made. For nausea, ropinirole, pergolide and rotigotine versus placebo all demonstrated similar RRs (2.25 [95% CI 1.85, 2.74]; 2.28 [95% CI 1.54, 3.37]; and 2.08 [95% CI 1.30, 3.34], respectively). On indirect comparison of ropinirole with pramipexole, ropinirole showed a higher RR for nausea (2.25 [95% CI 1.85, 2.74] vs 1.48 [95% CI 1.24, 1.76]), dizziness (1.87 [95% CI 1.48, 2.37] vs 1.20 [95% CI 1.01, 1.43]), somnolence (2.45 [95% CI 1.30, 4.61] vs 1.68 [95% CI 1.25, 2.25]), and dyskinesia (2.71 [95% CI 1.74, 4.21] vs 2.27 [95% CI 1.58, 3.27]). Pramipexole (3.36 [95% CI 2.41, 4.68], pergolide (4.80 [95% CI 2.24, 10.29]), ropinirole (2.84 [95% CI 1.34, 5.99]), and rotigotine (4.02 [95% CI 1.23, 13.11]) all had a higher RR of hallucinations compared with placebo. Pramipexole also showed a higher RR of confusion (2.64 [95% CI 1.18, 5.91]) and constipation (2.23 [95% CI 1.53, 3.25]) compared with placebo.
Conclusions: In all the included studies, dopamine agonists, including ropinirole, exhibited a higher incidence of adverse events than placebo. Ropinirole showed an adverse event profile similar to other dopamine agonists. Consideration of the clinical characteristics of each patient and the differences in the incidence of adverse events related to each dopamine agonist, may help to optimize the dopamine agonist therapy.
Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm Suppl 1995; 45: 213–24PubMed
Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson’s disease. Am J Health Syst Pharm 1999 Feb 1; 56(3): 217–24PubMed
Delgado M, Domenench J. Revisión sistematica de metaa-nálisis. 7th ed. Madrid: Diseño de Estudios Sanitarios, 2002
Jost WH. Ropinirole: current status of the studies. J Neurol 2004 Sep; 251 Suppl. 6: VI/13-8
Anderson P. Cochrane reviewer’s handbook 4.2.2. Chichester: The Cochrane Library, 2004
Higgins JPT. Cochrane handbook for systematic reviews of interventions. Version 5.0.1. The Cochrane Collaboration, 2008 [online] Available from URL: http://www.cochrane-handbook.org [Accessed 2009 Dec 10]
Parlodel: summary of product characteristics. Basilea: Novartis, 2003 [online]. Available from URL: http://www.pharma.us.novartis.com/products/name/parlodel.jsp [Accessed 2010 Jan 5]
Sogilen: summary of product characteristics. New York: Pfizer, 2005 [online]. Available from URL: http://www.pfizer.es/para/profesionales_sanitarios/login.html?ReturnUrl=/para/profesionales_sanitarios/medicamentos/sogilen.html [Accessed 2007 Dec 18]
Mirapex: summary of product characteristics. Ingelheim: Boehringer, 2003 [online]. Available from URL: http://www.mirapex.com/pd/ [Accessed 2010 Jan 6]
Requip: summary of product characteristics. London: GlaxoSmithKline, 2002 [online]. Available from URL: http://www.gsk.com/products/prescription-medicines/requip.htm [Accessed 2010 Jan 5]
Neupro: summary of product characteristics. Monheim: Schwartz Pharma, 2006 [online]. Available from URL: http://www.ucb.com/products/product-list/cns/neupro [Accessed 2010 Jan 5]
Pergolide: summary of product characteristics. Indianapolis (IN): Lilly, 2004 [online]. Available from URL: http://www.pharken.com/index.jsp [Accessed 2007 Dec 18]
The Parkinson Study Group. Controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8CrossRef
Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997 Jul 9; 278(2): 125–30CrossRef
Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 2007 Mar–Apr; 30(2): 72–85CrossRef
Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopa-minergic therapy in Parkinson’s disease. Clin Neuro-pharmacol 1998 Mar–Apr; 21(2): 101–7
Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease. J Neural Transm Suppl 1995; 45: 225–30PubMed
Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 2003 Oct; 18 Suppl. 7: S16-21
Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000 Oct 18; 284(15): 1931–8CrossRef
- Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease
Volume 33, Issue 2 , pp 147-161
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Unit of Movement Disorders, Neurology Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maréa Claret, 167, 08025, Barcelona, Spain
- 2. CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), Instituto de Salud Carlos III, Madrid, Spain